HyperRHO S/D Full Dose

HyperRHO S/D Full Dose Indications/Uses

anti-d immunoglobulins

Manufacturer:

Grifols

Distributor:

Grifols Asia Pacific
Full Prescribing Info
Indications/Uses
Pregnancy and Other Obstetric Conditions: HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant, providing the following criteria are met: The mother must be Rho(D) negative and must not already be sensitized to the Rho(D) factor.
Her child must be Rho(D) positive, and should have a negative direct antiglobulin test (see Precautions).
If HyperRHO S/D Full Dose is administered antepartum, it is essential that the mother receive another dose of HyperRHO S/D Full Dose after delivery of an Rho(D) positive infant.
If the father can be determined to be Rho(D) negative, HyperRHO S/D Full Dose need not be given.
HyperRHO S/D Full Dose should be administered within 72 hours to all nonimmunized Rho(D) negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rho(D) negative. If the fetal blood group cannot be determined, one must assume that it is Rho(D) positive, and HyperRHO S/D Full Dose should be administered to the mother.
Transfusion: HyperRHO S/D Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in